Please assess the completion status of the following clinical trial:

Trial Title: The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of a hemolytic disorder including spherocytosis, G6PD deficiency, thalassemia or sickle cell disease.~2. Patients with cholelithiasis or bile sludge.~3. Age greater than or equal to 4 years.~4. Ability to consent to and participate in the study and follow study procedures.~Exclusion Criteria:~1. Previous splenectomy (complete or partial)~2. Evidence of hemolytic crisis at the time of research enrollment~3. Patients with highly symptomatic gallstones who have planned surgical intervention~4. Known allergy or intolerance to UDCA~5. Existence of concurrent hepatic disease~6. Any other laboratory or clinical condition that the investigator considers clinically significant that could impact the outcome of the study or the safety of the patient.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): 32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).

Based on this trial design, predict the completion outcome and termination type (if applicable).